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CObjective: In Germany, only limited data are available to quantify the
attributable resource utilization associated with adverse drug events
(ADEs). The aim of this study was twofold: first, to calculate the direct
treatment costs associated with ADEs leading to hospitalization and,
second, to derive the excess costs and extra hospital days attributable
to ADEs of inpatient treatments in selected German hospitals.
Methods: This was a retrospective and medical record–based study
performed from the hospitals’ perspective based on administrative ac-
counting data from three hospitals (49,462 patients) in Germany. Total
treatment costs (“analysis 1”) and excess costs (i.e., incremental re-
source utilization) between patients suffering from an ADE and those
without ADEs were calculated by means of a propensity score–based
matching algorithm (“analysis 2”). Results: Mean treatment costs
“analysis 1”) of ADEs leading to hospitalization (n 564) were €1,978
,036 (range €191–18,147; median €1,446; €843–2,480 [Q1–Q3]). In analy-
is 2, the mean costs of inpatients suffering from an ADE (n 1,891) as O
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ttp://dx.doi.org/10.1016/j.jval.2012.05.007concomitant disease or complication (€5,113  10,059; range €179–
46,288; median €2,701; €1,636–5,111 [Q1–Q3]) were significantly higher
€970; P  0.0001) than those of non-ADE inpatients (€4,143  6,968;
ange €154–148,479; median €2,387; €1,432–4,701 [Q1–Q3]). Mean inpa-
ient length of stay of ADE patients (12.7  17.2 days) and non-ADE
atients (9.8 11.6 days) differed by 2.9 days (P 0.0001). A nationwide
xtrapolation resulted in annual total treatment costs of €1.058 billion.
onclusions: This is one of the first administrative data–based analy-
es calculating the economic consequences of ADEs in Germany. Fur-
her efforts are necessary to improve pharmacotherapy and relieve
ealth care payers of preventable treatment costs.
eywords: adverse drug events, cost accounting, diagnosis related
roups, hospitalization.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Drug therapies are associatedwith a risk of patients suffering from
adverse drug events (ADEs), whichmay result in moderate to fatal
treatment outcomes. ADEs occur frequently in both ambulatory
and inpatient settings and often lead to hospitalization; these
events occurmore often in the elderly [1–3].ADEs are defined as an
njury resulting frommedical interventions related to drugs either
aused by medication errors or occurring despite proper drug us-
ge [4–6]. Hence, ADEs may result from medication errors at any
tage in the medication process (e.g., dispensing or administra-
ion) or from adverse drug reactions (ADRs) [7]. In Germany, recent
tudies indicate that no significant improvements in drug safety
ave been realized in recent years, resulting in many iatrogenic
isks of drug therapy and insufficient patient safety [8–11]. Besides
requently preventable losses in quality of life and life expectancy,
DEs are associated with considerable costs for both payers and
ealth care providers [12,13]. A review of selected international
tudies regarding the economic consequences of ADEs reported
dditional mean costs in the range of €934 to €5783 per case [14].
tark et al. [15] reported costs of €816 million for ADEs resulting
* Address correspondence to: Dominik Rottenkolber, Ludwig-Ma
ealth Care Management, Ludwigstr. 28 RG V, 80539 Munich, Germ
E-mail: rottenkolber@bwl.lmu.de.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.rom outpatient treatment based on a 1-year-period probability
athwaymodel. Despite the widespread agreement that ADEs are
xpensive, limited studies have been conducted from the hospital
erspective. In this context, Bates et al. [16] estimated the ADE-
nduced annual overall costs to be $8000 per hospital bed. Costs
ere mostly assessed from the payers’ perspective on the basis of
he calculation of reimbursement tariffs. This particularly ne-
lects the growing economic importance of treating ADE patients
n hospitals under severe cost constraints. No conclusions can be
rawn from prior studies, whether treatment patterns can be per-
ormed cost-covering. The objectives of our study were twofold:
rst, the treatment costs of ADE-induced hospitalizations were
alculated (“analysis 1”) and, second, the excess costs (i.e., the
dditional resource consumption; “analysis 2”) of inpatients suf-
ering from anADE as a concomitant disease or complicationwere
ompared with those of a respective control group (non-ADE pa-
ients) by using a propensity score matching approach. Both ob-
ectives were performed from the hospitals’ perspective. A micro-
osting approach based on resource consumption data from three
elected German hospitals was applied. To the best of our knowl-
dge, this is one of the first studies based on administrative data to
alculate the economic consequences attributable to ADEs.
ilians-Universität München, Institute of Health Economics and
.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Data description
Data for this retrospective analysis were collected from January 1,
2008, to December 31, 2008, in three public utility service hospitals
including a total capacity of 1,208 beds (hospital A: 260, hospital B:
490, and hospital C: 458) in Berlin, Germany. The study base pop-
ulation consisted of 49,462 patients (hospital A: 10,776 [21.8%],
hospital B: 17,851 [36.1%], and hospital C: 20,835 [42.1%]) who were
hospitalized during this period (excluding inpatient deliveries).
Computerized medical records were stored in the hospital infor-
mation systems and compiled for the analyses.
Clinical, demographic, and economic data were analyzed to
describe the patient sample and calculate the treatment costs. The
International Statistical Classification of Diseases and Related Health
Problems, 10th Revision, German modification (ICD-10-GM), is used for
coding inpatients in German hospitals. The main reason for ad-
mission would be given as the primary diagnosis. Data collected
from all patients included primary and secondary diagnoses (i.e.,
concomitant diseases and complications), age, sex, length of stay
(LOS), and performed surgeries. Statistical data for the nationwide
extrapolation were retrieved from the Federal Statistical Office in
Germany [17].
Identification of ADEs
For the identification of ADEs, an algorithm (published elsewhere
[6,18]) developed by two of the authors was applied. Suitable ICD
codes grouped into the following categories (labeled A–C) were
considered: “caused by a drug” (A.1), “caused by a drug or other
substance” (A.2), “poisoning by drug” (B.1), “poisoning by or harm-
ful use of a drug or other substance” (B.2), and “ADE very likely” (C).
It is acknowledged, however, that concerning the two categories
A.2 and B.2, other substances or measures may have caused the
adverse event (e.g., “mental and behavioural disorders due to use
of opioids” [ICD F11], “mental and behavioural disorders due to
multiple drug use and use of other psychoactive substances” [F19],
or “abuse of non-dependence-producing substances” [F55]). The
recording of an ADE requires the identification of a drug as the
cause of the symptom or the disease. This identification may
be difficult, but it is imperative when using the specific codes of
the ICD-10-GM (categories A.1, A.2, B.1, and B.2). A bias due to the
inclusion of other causes (e.g., self-poisoning and suicide at-
tempts) in categories “A.2” and “B.2” is acknowledged but must be
accepted given the variety of different causes covered by a single
ICD-10 code. In total, this selection included 360 ICD codes that
were applied to our data set. Patients with relevant ICD codes in
their primary diagnoses were selected in a first step (“analysis 1”).
In these cases, a causal relationship between ambulatorily sus-
tained ADEs and hospitalization can certainly be assumed, as the
primary diagnosis was recorded to be the reason for hospitaliza-
tion. Secondary diagnoses are concomitant diseases at the time of
admission or complications that developed during hospitaliza-
tion. We assumed that ICDs indicating an ADE as secondary diag-
nosis developed during hospitalization (“analysis 2”). This ap-
proach is in line with the German coding standards (“Deutsche
Kodierrichtlinen”) [19]. ADE detectionwas performed in both anal-
yses in the total population described above.
Cost determination and calculation
Direct medical costs were calculated from the perspective of the
treating hospitals. The data set is part of the mandatory annual
report to the Institute for the Hospital Remuneration System
(InEK) in order to calculate the diagnosis related groups reim-
bursement tariffs in Germany (§21 KHEntgG). Cost application to
the cost unit “treatment case” is based on actual costing, wherebyonly costs and services covered by diagnosis related group reim-
bursement principles are considered [19]. Our analyses are based
on a bottom-up approach (“microcosting”) to estimate the true
economic costs, whereby all services rendered are collected in-
depth and monetary values are assigned [20,21]. Microcosting
systems specify every resource consumed in health care service
provision and assign its unit costs. This enables both high trans-
parency and accuracy for cost assessment. For the retrieved ADE
treatment cases, the relevant costs were determined and total
costs were calculated for each cost unit (i.e., patient). The treat-
ment costs per patient were assessed by summing all single cost
components that contributed to the inpatient treatment. The rel-
evant cost types for this study were retrospectively derived from
the hospitals’ in-house cost-unit accounting based on routine data
(“InEK-Matrix”) [22]. For the calculation of treatment costs, the
following cost categories were covered: personnel (i.e., clinicians,
nursing staff, and medical technicians) and nonpersonnel costs
(i.e., pharmaceuticals, implants, grafts, and medical expenditure
not otherwise specified) and personnel and material costs for
medical and nonmedical infrastructure. Responsible cost centers
were general ward, intensive care units, operating room, anesthe-
sia, cardiac and endoscopic diagnostics and therapies, radiology,
laboratory tests, and diagnostic and therapeutic areas not other-
wise specified. For ADEs causing hospitalization, the total (annual)
costs and LOS were assigned to these events. Hence, the term
“cost” is defined as total hospital costs.
Statistical analyses
The excess costs of inpatients suffering fromADEs comparedwith
non-ADE patients were calculated as the difference between cases
and control subjects for each patient (“analysis 2”). Hence, we
matched cases and control subjects in a stepwisemanner by using
a propensity score matched-pair approach called “greedy 5¡1
matching algorithm” [23]. This methodmatches cases and control
subjects on known attributes to create a control group thatmimics
the case group. Cases were those patients exhibiting an ADE in
secondary diagnoses. Control subjects were selected by creating a
comparison group by calculating a propensity score (performed
via multivariate logistic regression) controlling for the patients’
individual patient clinical complexity level, which reflects the se-
verity of comorbidity, the major diagnostic category, sex, and the
patients’ age at the time of admission [24]. Each case wasmatched
to one control subject. Patients suffering frommultiple ADEs were
considered only once in the economic analysis. Statistical analy-
ses were performed by using SAS statistical software, version 9.2
(SAS Institute, Inc., Cary, NC). All metric and normally distributed
variables were reported as mean  SD, range, and median; non-
normally distributed data and cost data were reported as mean 
D, range, and median (including first quartile [Q1]–third quartile
Q3]). Categorical variables were presented as frequency and per-
entage. P values of less than 0.05 were considered to be statisti-
ally significant (Mann-Whitney U test).
Results
Patient demographics
In our total population (n  49,462), 51.6% of the patients were
women (n  25,543) and 48.4% of the patients were men (n 
23,919). The mean age was 56.6  23.6 years (range 0–106 years,
median 63 years). The mean inpatient LOS was 6.8  8.7 days
(range 0–273 days; median 4 days; 2–9 days [Q1–Q3]). In total, the
cumulative hospitalization time was 335,961 days, with no sig-
nificant difference between women and men. The 10 most com-
mon primary diagnoses (24.9%; 12,339 patients) are displayed in
Table 1.
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(ADEs causing admissions)
Application of the ADE detection algorithm to this population
identified 564 patients (1.14%) who had been hospitalized on ac-
count of an ADE classified by one of the ICD codes selected above
(Table 2).
The mean age of these patients (“analysis 1”) was 47.4  23.2
years (range 0–96 years; median 43.5 years). Female sex was pre-
dominant (n  297, 52.7%). The mean inpatient LOS was 6.2  6.9
days (range 0–59 days; median 4 days; 1–9 days [Q1–Q3]). Most
frequent single diagnoses were “enterocolitis due to Clostridium
difficile” (A04.7; n  78), “mental and behavioural disorders due to
multiple drug use and use of other psychoactive substances: with-
drawal state” (F19.3; n  44), and “mental and behavioural disor-
ders due to use of opioids: dependence syndrome” (F11.2; n  34).
Table 3 provides an overview of themost frequent ADEs including
the costs per ICD group (three-character categories).
Total hospitalizations summed to 3,502 days. The mean total
treatment costs were calculated to be €1,978 €2,036 (range €191–
18,147; median €1,446; €843–2,480 [Q1–Q3]) per case. Most expen-
sive treatment cases were “complications following infusion,
transfusion, and therapeutic injection” (€3,527  €3,789; range
€317–13,060; median €2,602; €655–5,035 [Q1–Q3]), “toxic liver dis-
ease” (€3,101  €3,334; range €211–18,147; median €2,832; €1,270–
3,407 [Q1–Q3]), “other bacterial intestinal infections” (€3,083 
Table 1 – Description of most frequent primary
diagnoses (base population).
Rank ICD code
(three digits)
Description n (%)
1 G47 Sleep disorders 1,998 (4.04)
2 I70 Atherosclerosis 1,660 (3.36)
3 I50 Heart failure 1,535 (3.10)
4 C34 Malignant neoplasm of
bronchus and lung
1,491 (3.01)
5 I20 Angina pectoris 1,415 (2.86)
6 F10 Mental and behavioral
disorders due to use of
alcohol
923 (1.87)
7 I48 Atrial fibrillation and flutter 843 (1.70)
8 K80 Cholelithiasis 839 (1.70)
9 C50 Malignant neoplasm of
breast
828 (1.67)
10 I21 Acute myocardial infarction 807 (1.63)
11 NA Others 37,123 (75.06)
ICD, International Classification of Diseases; NA, not applicable/
available.
Table 2 – Classification and frequency of ADEs.
Level Description
ADEs leading to
(i.e., ADEs cod
diag
A1 Caused by a drug 52 (
A2 Caused by a drug or other substance 222 (
B1 Poisoning by drug 133 (
B2 Poisoning by or harmful use of a
drug or other substance
16 (
C ADE very likely 141 (
— Total 564 (ADEs, adverse drug events.€2,725; range €475–15,443; median €2,316; €1,531–3,532 [Q1–Q3]),
and “poisoning by hormones and their synthetic substitutes and
antagonists, not elsewhere classified” (mean €2,607  €737; range
€1,669–3,597; median €2,711; €1,847–3,110 [Q1–Q3]). In the study
period, total costs in the respective hospitals for patients admitted
as the result of an ADE were €1.12 million.
Treatment costs attributable to inpatient ADEs
(occurring during hospitalization)
In total, 2049 ADEs coded in secondary diagnoses occurred. Some
1748 patients (92.3%) suffered from one ADE, 137 patients (7.2%)
from two ADEs, and 9 patients (0.5%) from three ADEs.
More than three fourth of all ADEswere classified as “caused by
a drug or other substance” (55.4%) and “caused by a drug” (22.5%).
In contrast to ambulatorily acquired ADEs (26.4%), the categories
“poisoning by drug” and “poisoning by a harmful use of a drug or
other substance” accounted for only 6.3% of the ADEs (Table 2). In
addition, Table 4 provides an overview of the most frequent ADEs
per ICD group (three-character categories).
Calculating the excess costs (i.e., the additional resource use) of
inpatient treatment attributable to an ADE (“analysis 2”) resulted
in 1891 treatment cases (3.8% of the hospitalizations) that oc-
curred in the hospital during the study period. In this subsample,
1095 patients were females (57.9%) and 796 were males (42.1%).
Cases were matched to the respective control subjects accord-
ing to the approach described in the Methods section. The results
are displayed in Table 5.
Patients who were identified as suffering from an ADE were
associated with significantly higher average treatment costs of
€970 (median €314) per patient (€5,113  10,059; range €179–
246,288; median €2,701; €1,636–5,111 [Q1–Q3]) than people in the
control group (€4,143  6,968; range €154–148,479; median €2,387;
€1,432–4,701 [Q1–Q3]) and required an extended hospital stay of
2.9 (median 1.0 day) extra days (P  0.0001). Table 6 provides a
ummary of the differences in LOS and the excess costs between
ases and control subjects. Annual total treatment costs in ADE
atients (€9.67 million) exceeded those in non-ADE patients (€7.83
illion) by €1.84 million.
Extrapolation of our results to the national level resulted in a
ubstantial economic burden for German hospitals. For patients
ith an ADE as primary diagnosis (“analysis 1”), total costs
mount to approximately €457 million (16.5 million patients 
.014 €1978). For patients with an ADE as a concomitant disease
r complication (“analysis 2”), excess costs equal approximately
601million (16.3 million patients 0.038 €970) and ADEsmay
um to a total of 1.8 million extra days of hospitalization (16.3 mil-
ionpatients0.0382.9days).Considering thesefigures, onemight
stimate that ADEs cause total direct costs of €1.058 billion per year.
n (%)
pitalization
s primary
)
ADEs acquired during inpatient treatment
(i.e., ADEs coded as secondary diagnosis)
461 (22.5)
1136 (55.4)
94 (4.6)
35 (1.7)
323 (15.8)
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In our study, we identified a substantial number of ADEs (n 564)
that were highly likely to have resulted in hospitalizations with
costs of €1,978  €2,036 (range €191–18,147; median €1,446; €843–
2,480 [Q1–Q3]) per patient (“analysis 1”). In the second part, the
mean excess treatment costs of ADE patients equal €970 (median
€314) and the respective control subjects (n  1,891) were calcu-
ated (“analysis 2”). Total annual nationwide costs were estimated
o be €1.058 billion. Considerable similarities in the economic con-
equences of ADEs, but also a number of differences (particularly
hen focusing on epidemiology), exist between this and previous
tudies. Ambulatory ADEs often lead to hospitalization and occur
n 1.4% to 15.4% of the hospitalized patients [18,25,26]. The admis-
ion rate frequency that we identified in our sample (1.14%) was
ower than the 2% to 15% attributable to ADEs reported elsewhere
5,27,28]. The differencemay result from the young patient sample
mean age 47.4 years) or the possibility that the detection algo-
ithm missed ADEs included in other studies. Regarding ADEs oc-
urring after hospitalization, our result (3.8%) is in linewith that of
Table 3 – Classification of ADEs leading to hospitalization (
Rank ICD code
(three digits)
Description
1 A04 Other bacterial intestinal infections
2 F19 Mental and behavioral disorders due to
multiple drug use and use of other
psychoactive substances
3 F11 Mental and behavioral disorders due to us
opioids
4 T42 Poisoning by antiepileptic, sedative-hypno
and antiparkinsonism drugs
5 F13 Mental and behavioral disorders due to us
sedatives or hypnotics
6 K71 Toxic liver disease
7 T43 Poisoning by psychotropic drugs, not
elsewhere classified
8 T78 Adverse effects, not elsewhere classified
9 T40 Poisoning by narcotics and psychodyslept
(hallucinogens)
10 D69 Purpura and other hemorrhagic condition
11 D70 Agranulocytosis
12 D61 Other aplastic anemias
13 T88 Other complications of surgical and medic
care, not elsewhere classified
14 T50 Poisoning by diuretics and other unspecifi
drugs, medicaments, and biological
substances
15 T39 Poisoning by nonopioid analgesics,
antipyretics, and antirheumatics
16 T80 Complications following infusion,
transfusion, and therapeutic injection
17 K52 Other noninfective gastroenteritis and col
18 T45 Poisoning by primarily systemic and
hematological agents, not elsewhere
classified
19 T46 Poisoning by agents primarily affecting th
cardiovascular system
20 I95 Hypotension
21 T38 Poisoning by hormones and their syntheti
substitutes and antagonists, not elsewh
classified
22 — Others
Total
ADEs, adverse drug events; ICD, International Classification of Diseases.enst et al. [28], who reported anADE rate of 4.2% in a four-hospital sealth care network in the United States. Considering LOS in ADEs
ausing admission to hospital, our results (median 4 days) are
omparable to those presented in the literature. Jha et al. [25] re-
orted a median stay of 5 days for ADE patients who were hospi-
alized. Various research groups calculated an (average) LOS in-
rease of between 0.77 and 2.2 days attributable to ADE patients,
hich is comparable to the extra days in our study [16,28–31].
reventability of ADEs is estimated to vary between 30% and
0% according to various studies, and half of the preventable
DEs require hospital admission [5,25,32–34]. This could reveal
significant savings potential for the hospitals. ADE cases in
ategories “A.2” to “B.2” are classified as type A reactions and
ecover after a reduction in drug dosage. Although many events
re predictable, however, they are not always preventable [35].
o date, no satisfactory approach has been developed on this
ssue [36,37]. When a reviewer classifies an event as definitely or
robably preventable, it remains ambiguous whether there is a
0% or a 10% chance that the event could have actually been
revented if care had been optimal [38]. But the transfer of these
robability elements into economic studies has not been con-
ary diagnoses).
n (%) Costs (€),
mean  SD
Range (€) Median costs (€)
(Q1–Q3)
78 (13.8) 3,083  2,725 475–15,443 2,316 (1,531–3,532)
72 (12.8) 1,708  852 208–4,352 1,667 (1,172–2,321)
64 (11.4) 1,387  861 208–3,881 1,344 (708–1,820)
44 (7.8) 1,280  788 232–4,128 1,011 (797–1,655)
31 (5.5) 2,164  1,131 280–4,223 2,068 (1,234–3,178)
29 (5.1) 3,101  3,334 211–18,147 2,832 (1,270–3,407)
26 (4.6) 1,536  1,472 409–7,580 1,010 (697–1,916)
24 (4.3) 1,131  1,337 223–5,317 662 (384–1,224)
20 (3.6) 2,235  3,585 320–16,262 914 (512–2,138)
19 (3.4) 2,040  1,926 615–7,511 1,392 (970–2,478)
17 (3.0) 1,436  763 191–3,336 1,240 (1,126–1,432)
16 (2.8) 1,548  1,412 500–5,265 880 (651–1,599)
15 (2.7) 1,992  3,883 271–15,884 983 (532–1,772)
15 (2.7) 1,079  819 334–3,320 744 (472–1,501)
14 (2.5) 1,645  2,413 358–9,951 1,023 (828–1,441)
11 (2.0) 3,527  3,789 317–13,060 2,602 (655–5,035)
10 (1.8) 2,349  1,717 577–6,674 2,163 (1,035–2,595)
9 (1.6) 2,100 (1,381) 388–3,964 1,418 (1,090–3,303)
8 (1.4) 2,541  2,010 958–6,831 1,796 (1,142–3,331)
7 (1.2) 1,507  732 411–2,528 1,374 (1,183–2,383)
6 (1.1) 2,607  737 1,669–3,597 2,711 (1,847–3,110)
29 (4.9) 1,854  1,516 304–6,949 1,373 (645–2,497)
564 (100.0) 1,978  2,036 191–18,147 1,446 (843–2,480)prim
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872 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 8 – 8 7 5Accurate costs associated with ADEs are rarely known, and
earlier studies determined these costs through a wide variety of
methodological approaches and definitions. So far, economic data
on ADEs provide a heterogeneous landscape and prior results are
Table 4 – Description of ADEs acquired during hospitalizat
Rank ICD code
(three digits)
1 T88 Other complications of surgical
2 D61 Other aplastic anemias
3 F13 Mental and behavioral disorder
4 D69 Purpura and other hemorrhagic
5 E03 Other hypothyroidism
5 T78 Adverse effects, not elsewhere
7 A04 Other bacterial intestinal infect
8 D70 Agranulocytosis
9 M81 Osteoporosis without pathologi
10 K71 Toxic liver disease
11 F11 Mental and behavioral disorder
12 F19 Mental and behavioral disorder
psychoactive substances
13 T45 Poisoning by primarily systemi
14 T80 Complications following infusio
15 L27 Dermatitis due to substances ta
16 T46 Poisoning by agents primarily a
17 — Others
Total
ADEs, adverse drug events; ICD, International Classification of Diseases.
Table 5 – Matching results.
Variable Identifier
Sex, n (%) Female
Male
Age (y) Mean  SD
PCCL, n (%) 0 (no complication or comorbidity)
1 (minor complication or comorbidity)
2 (moderate complication or comorbidity)
3 (severe complication or comorbidity)
4 (catastrophic complication or comorbidity)
MDC, n (%) 1 (Diseases & Disorders of the Nervous System)
3 (Diseases & Disorders of the Ear, Nose, Mouth, & Throa
4 (Diseases & Disorders of the Respiratory System)
5 (Diseases & Disorders of the Circulatory System)
6 (Diseases & Disorders of the Digestive System)
7 (Diseases & Disorders of the Hepatobiliary System & Pa
8 (Diseases & Disorders of the Musculoskeletal System &
9 (Diseases & Disorders of the Skin, Subcutaneous Tissu
10 (Endocrine, Nutritional, & Metabolic Diseases & Disor
11 (Diseases & Disorders of the Kidney & Urinary Tract)
12 (Diseases & Disorders of the Male Reproductive Syste
13 (Diseases & Disorders of the Female Reproductive Sys
14 (Pregnancy, Childbirth, & the Puerperium)
15 (Newborns & Other Neonates)
16 (Diseases & Disorders of Blood, Blood-Forming Organ
17 (Neoplastic Disorders [Hematological & Solid Neoplas
18B (Infectious & Parasitic Diseases, Systemic or Unspec
19 (Mental Diseases & Disorders)
20 (Alcohol/Drug Use & Alcohol/Drug-Induced Organic M
21B (Injuries, Poisonings, & Toxic Effects of Drugs)
23 (Factors Influencing Health Status & Other Contacts wMDC, major diagnostic category; PCCL, patient clinical complexity level.scarcely comparable because of the different national health care
settings and their specifics (e.g., patient mix, institutional pro-
cesses, and different methods for prescribing and dispensing
drugs), the patients’ individual context, and different methods
ADEs coded as secondary diagnoses).
escription n (%)
medical care, not elsewhere classified 583 (28.5)
196 (9.6)
to use of sedatives or hypnotics 157 (7.7)
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2,049 (100.0)
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1095 (57.91) 1097 (58.01)
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873V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 8 – 8 7 5used to achieve medication adherence. In the United States, Bates
et al. [32] calculated the costs of preventable inpatient events to be
$2 billion. Dartnell et al. [39] reported the annual costs to be ap-
proximately $3 million (Australian academic hospital). Bates et al.
[16] estimated the excess costs associated with an ADE to be $3244
nd overall costs to a hospital to be $5.6 million per year (US 700-
ed teaching hospital). Jha et al. [25] mention annual costs of $6.3
million for all admissions resulting fromADEs, and $1.2million for
preventable ADEs that led to admission to a large academic US
hospital. But the authors note that the events revealed were very
expensive. Senst et al. [28] calculated an average increase in costs
f $2162 for a patient suffering from an ADE that occurred after
ospitalization (annual extrapolated costs of $1.7 million) and
6685 per case for ADEs causing admission to hospital (annual
rojected sum equaled $4.9 million). Field et al. [40] calculated the
costs associated with ADEs among older adults in an ambulatory
setting for 6 weeks before and 6 weeks after the ADE occurred,
resulting in a cost increase of $1310. Considering the accountabil-
ity of costs with respect to their origin, it is known that by covering
ADRs leading to hospitalization, even ADR-associated risks in out-
patient treatment are incorporated [41].
Limitations
Our study, however, faces several limitations. First, the nation-
wide extrapolation of our economic estimates should be kept in
perspective as the preselection of three hospitals in a single geo-
graphic region may not be representative of all German hospitals
(failure to account for clinical heterogeneity by pooling all data)
because differences may exist in costs, medical treatment pat-
terns, and hospital care levels. The large proportion of mental and
behavioral disorders (approximately a quarter of all ADE-induced
hospitalizations) and the lower patients’ average age (47.4 years)
seem to result from this selection, as it differs from those reported
in international studies (e.g., 6% mental disorders and 5% injury/
poisoning) with mostly elderly patients suffering from ADEs [27].
Quite apart from that, our study is unique on account of its more
comprehensive cost survey approach. Second, we refrained from
considering categories “D” (i.e., “ADE likely”) and “E” (i.e., “ADE
possible”) in ADE detection, which pertain to ADEs but are associ-
ated with considerable uncertainty [18]. Third, the analysis of ad-
ministrative data is limited on account of several restrictions (e.g.,
hospital-specific differences in coding practices) [42]. As datawere
collected for accounting purposes, overall data quality is extraor-
dinary, but the course of disease is not adequately displayed for
subsequent use [24,43]. No comprehensive data sources are avail-
able in Germany, covering the whole drug treatment process in all
stages. Other possible databases are the database of ADR-induced
hospitalizations to departments of internal medicine provided by
the Federal Institute for Drugs and Medical Devices (BfArM) or the
population-based German Pharmacoepidemiological Research
Database (GePaRD-BIPS) covering Statutory Health Insurance and
Table 6 – Length of stay and excess costs.
Cases
(n  1,891)
Length of stay (d)
Mean  SD 12.7  17.2
Median (Q1–Q3) 8.0 (4.0–15.0)
Range 0–273
Costs (€)
Mean  SD 5,113  10,059
Median (Q1–Q3) 2,701 (1,636–5,111)
Range 179–246,288prescription information [44,45]. These, however, do not containdetailed information on inpatient resource consumption during
hospitalization.
Fourth, various studies reported a limited number of drugs to
be themost frequent cause of ADE-related hospital admissions. In
a systematic review and data synthesis, Howard et al. [46] found
that preventable drug-related hospital admissionswere caused by
antiplatelets (16.0%), diuretics (15.9%), nonsteroidal anti-inflam-
matory drugs (11.0%), and anticoagulants (8.3%). In Germany, Sch-
neeweiss et al. [45] found that most ADRs were on account of
cardiovascular drugs, antithrombotics, analgesics, andantirheumat-
ics. In another German study, Dormann et al. [47] reported central
nervous system, cardiovascular, and anti-infective agents to be the
most common causative drugs of ADEs resulting in (re-)hospitaliza-
tion. In this study, similar drugs were supposed to be the cause of
hospitalization. There was, however, a strong emphasis on anti-
biotics (about 14%), antipsychotic/sedatives (25%), and opiates
(11%), which was affected by the selection of the three hospitals.
In addition, the ICD-10–based identification of drug-induced
events is not comprehensive in scope, as consistent secondary
codes (e.g., Y40–59.9) are required for more precise ADE detection
[48,49]. Hence, it cannot be assumed that these already existed at
the time of admission or occurred during the hospital stay. A sub-
sequent separation between existing ADEs and those that devel-
oped while hospitalized is impossible.
Fifth, we did not adjust for pre-ADE hospitalization (because
this was unfeasible from our data), which is known to be an im-
portant confounder [16,29]. Beyond that, we did not have any data
on prehospital drug utilization, preventability, and severity of
ADEs. This impedes the determination of delayed effects and end-
of-treatment effects. Last, the calculation of excess costs is im-
paired by the small sample size and the patient characteristics
included in the propensity score calculation (i.e., major diagnostic
category and patient clinical complexity level) [50]. The caseswere
matched with control subjects on severity, comorbidity, and pa-
tient sociodemographics to estimate excess costs and LOS attrib-
utable to ADEs. A reflection of disease patterns by the inclusion of
diagnosis related group would improve the quality of matching
considerably.
Managerial implications
Our results highlight the considerable costs associated with both
inpatient and outpatient ADEs. Hence, this study supports health
policy decision-makers in supporting the allocation of research
grants, estimating the impact of ADEs on the German health care
systems, analyzing the provision of health care patterns that en-
compass the risk of ADEs, and forecasting future demand for ADE-
related health care provision when translated to a nationwide pa-
tient population. The hospital management could use our
methodological approach to identify the relevant cost drivers, to
detect the magnitude of ADEs in their institution, to analyze the
provision of health care against the background of ADEs, to rede-
Control subjects
(n  1,891)
Difference
9.8  11.6 2.9
7.0 (3.0–13.0) 1.0
0–161 —
4,143  6,968 970
2,387 (1,432–4,701) 314
154–148,479 —sign medical service processes, to decide on the implementation
874 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 6 8 – 8 7 5of evidence-based medicine treatment patterns, and to evaluate
the effectiveness and prioritization of prevention strategies (e.g.,
clinical decision support systems) [51,52]. Particularly if patients
suffer frommultiple ADEs, or the ADE is not the primary diagnosis
in coding processes, thismay impose serious problems. Hence, the
preventability of these events is difficult to quantify. In this con-
text, actual results show that structured pharmaceutical supervi-
sion provides more effective results in drug therapy [53]. Pharma-
cists are enabled to offer an enhanced counseling interview
(“medicines-use-reviews”) with patients to optimize the individ-
ual therapy in order to simplify drug regimens and reduce ADEs
[54,55]. Currently, however, only weak evidence exists onwhether
this pharmacist-led approach influences adherence or contributes
to a reduction in ADEs or medication-related hospitalizations
[56,57].
The capability for detecting and preventing potential ADEs by
the use of electronic patient records, computerized physician or-
der entry, and clinical decision support systems was identified in
previous studies, resulting in high ADR preventability when using
adequate decision support systems [58–61]. Studies from other
health care settings revealed high returns on investment and a
significant lowering of both inpatient LOS and total costs [62,63]. In
a cutting-edge evaluation study, Wu et al. [64] calculated the cost-
effectiveness of a combined electronicmedication order entry and
medication administration record system from a Canadian hospi-
tal perspective. The analysis resulted in costs of $12,700 per ADE
avoided. This value appears to be high compared with the direct
costs of empirical studies. But it should be noted that specific hos-
pitals or rather departments (internal medicine) were considered,
and long-term consequences in particular are costly. Hug et al. [30]
reported that the majority (80%) of preventable ADEs (i.e., ADEs
that were due to an error or preventable by any means available)
would be avoided by powerful computerized physician order en-
try–related decision support. In addition, these authors present a
comprehensive compilation of the most important ADE preven-
tion strategies as a result of their research. The top five strategies
were drug-laboratory checks, renal function checks, drug-dose
suggestion, drug-age checks, anddrug-specific guidelines [30].Ma-
viglia et al. [65] conducted a cost-benefit analysis of the impact of
bar-code systems on ADEs in US academic hospitals. Potential
ADE rates decreased by 63%, and breakeven for return on invest-
ment was reached after 1 year of bringing the system into service.
Although the benefits of electronic prescribing and personal
health records are well established in inpatient hospital settings,
its contribution to patient safety in outpatient care remains am-
biguous [61,66]. Notwithstanding, these technical solutions are
suitable only to a limited extent, particularly if they are not inte-
grated into the decision-making process [67].
Conclusions
Wehave presented a practical and inexpensive approach to assess
ADE-associated resource consumption and estimate the fre-
quency of ADEs. To the best of our knowledge, no published study
has ever utilized these administrative data to calculate the eco-
nomic burden of ADEs. The matching approach allowed us to de-
rive cost and hospitalization estimates based on case and control
groups that share similar characteristics in disease patterns, pa-
tient characteristics, and medical severity. Prevention of ADEs by
improving medication safety in inpatient and outpatient care is
mandatory from both an economic and amedical point of view. In
conclusion, the substantial costs (almost a billion euros) associ-
ated with these events justify additional investments in efforts to
detect and prevent ADEs. Nevertheless, a methodologically accu-
rate attribution of hospital costs to ADEs is challenging. The anal-
ysis of administrative data can essentially contribute to the acqui-sition of pharmacovigilance knowledge, as small efforts in data
collection and high integrity allow new insights.
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